Literature DB >> 23920356

Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease.

Yoshiko Iwasaki1, Junichiro James Kazama, Hideyuki Yamato, Hiroshi Shimoda, Masafumi Fukagawa.   

Abstract

The prevalence of hip fracture is very high among patients with chronic kidney disease (CKD); however, the reason for this is unclear. We examined the effects of accumulated uremic toxins on bone chemical composition and elastic mechanical properties. Rats underwent thyroparathyroidectomy and progressive partial nephrectomy (TPTx-Nx), and were administered with vehicle or AST-120 to reduce serum indoxyl sulfate (IS) levels. Bone mechanical properties, bone mineral density (BMD), cortical bone chemical composition, and histomorphometry were determined. Storage modulus was reduced in TPTx-Nx rats compared with rats that underwent TPTx alone. BMD and histomorphometric parameters did not differ between the groups. In terms of cortical bone chemical composition, the mineral/matrix ratio and carbonate substitution was increased, whereas crystallinity was decreased in TPTx-Nx rats. The enzymatic crosslink ratio and pentosidine:matrix ratio were increased in TPTx-Nx rats. AST-120 abolished the effects of TPTx-Nx and decreased the serum IS concentration. Stepwise multiple regression analysis revealed that the pentosidine:matrix and mineral:matrix ratios were independent contributors to the storage modulus. In conclusion, the accumulated uremic toxins, including IS, seem to play an important role in deteriorating bone mechanical properties by altering the chemical composition of bone. This mechanism may account for the increased prevalence of hip fracture among patients with CKD.
© 2013.

Entities:  

Keywords:  AST-120; Chronic kidney disease; Storage module; Uremic toxins

Mesh:

Substances:

Year:  2013        PMID: 23920356     DOI: 10.1016/j.bone.2013.07.037

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  21 in total

1.  Not only for the risk of bone fracture.

Authors:  Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2015-05-12       Impact factor: 2.626

Review 2.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

Review 3.  Contributions of Raman spectroscopy to the understanding of bone strength.

Authors:  Gurjit S Mandair; Michael D Morris
Journal:  Bonekey Rep       Date:  2015-01-07

Review 4.  Uremic Toxicity and Bone in CKD.

Authors:  Suguru Yamamoto; Masafumi Fukagawa
Journal:  J Nephrol       Date:  2017-06-01       Impact factor: 3.902

5.  Chronic kidney disease and bone metabolism.

Authors:  Junichiro James Kazama; Koji Matsuo; Yoshiko Iwasaki; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2015-02-05       Impact factor: 2.626

Review 6.  Research progress on the relationship between IS and kidney disease and its complications.

Authors:  Yan Gao; Ye Li; Xueting Duan; Qian Wang; Haisong Zhang
Journal:  Int Urol Nephrol       Date:  2022-04-29       Impact factor: 2.266

Review 7.  Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly.

Authors:  Andrea Galassi; Paola Ciceri; Eliana Fasulo; Stefano Carugo; Giuseppe Cianciolo; Mario Cozzolino
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

8.  The effect of naturally occurring chronic kidney disease on the micro-structural and mechanical properties of bone.

Authors:  Anna Shipov; Gilad Segev; Hagar Meltzer; Moran Milrad; Ori Brenner; Ayelet Atkins; Ron Shahar
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

Review 9.  Uremic osteoporosis.

Authors:  Junichiro J Kazama; Yoshiko Iwasaki; Masafumi Fukagawa
Journal:  Kidney Int Suppl (2011)       Date:  2013-12

10.  Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease.

Authors:  Christopher L Newman; Sharon M Moe; Neal X Chen; Max A Hammond; Joseph M Wallace; Jeffry S Nyman; Matthew R Allen
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.